BryoLogyx is developing a new class of drugs to enhance the response rates and treatment durability of cancer immunotherapies and anti-HIV agents.

The company’s initial focus is on cancer, where it capitalizes on two recent scientific advances: the discovery that a complex natural product, bryostatin-1, stimulates tumor antigen production to amplify the immune response unleashed by cancer immunotherapy; and the invention of the first practical synthetic production method for bryostatin and analogs, enabling their availability for commercial development.

0 +

BryoLogyx has licensed exclusive rights from Stanford University to the method’s use in the areas of cancer and HIV. Bryostatin-1, currently in preclinical development for use with immuno-oncology agents. Bryostatin-1 has an established safety profile based on prior clinical studies involving more than 1100 patients.